低剂量率近距离放疗与根治性前列腺切除术后前列腺癌患者的长期第二恶性肿瘤
近距离放疗组15年和20年盆腔第二恶性肿瘤的Kaplan-Meier估计分别为6.4%和9.8%,根治性前列腺切除术组分别为3.2%和4.2%。多变量Cox分析显示,与手术相比,近距离放疗是盆腔第二恶性肿瘤(HR 1.81,95%CI 1.45-2.26,P<.001)和浸润性盆腔第二恶性肿瘤(HR 2.13,95%CI 1.61-2.83,P<.001)的独立因素。
要点
- 近距离放疗组15年和20年盆腔第二恶性肿瘤估计分别为6.4%和9.8%,根治性前列腺切除术组分别为3.2%和4.2%。
- 多变量分析中,近距离放疗对比手术的盆腔第二恶性肿瘤HR为1.81(95%CI 1.45-2.26,P<.001)。
- 浸润性盆腔第二恶性肿瘤HR为2.13(95%CI 1.61-2.83,P<.001),年龄增加和吸烟亦与事件估计升高相关(P<.001)。
核心结论
- 调整年龄、根治性前列腺切除术后辅助或挽救性外照射放疗状态和吸烟状态后,近距离放疗组相比根治性前列腺切除术组,盆腔和浸润性盆腔第二恶性肿瘤的长期HR数值上更高。
研究设计与样本
- 采用Kaplan-Meier法评估盆腔(膀胱和直肠)、浸润性盆腔、任何第二恶性肿瘤及任何第二恶性肿瘤死亡,并行Cox多变量分析,调整初始治疗类型、年龄、根治性前列腺切除术后辅助或挽救性外照射放疗状态和吸烟史。
主要发现
- 近距离放疗组中位年龄66岁(IQR 61-71),根治性前列腺切除术组63岁(IQR 58-67);至事件或删失的中位随访时间为14年(IQR 11.5-17.3)。
- 近距离放疗组15年和20年盆腔第二恶性肿瘤的Kaplan-Meier估计分别为6.4%和9.8%,根治性前列腺切除术组分别为3.2%和4.2%。
- 至任何第二恶性肿瘤的时间和至任何第二恶性肿瘤死亡的时间无显著差异(P > .05)。
- Cox多变量分析中,与手术相比,近距离放疗是盆腔第二恶性肿瘤(HR 1.81,95%CI 1.45-2.26,P < .001)和浸润性盆腔第二恶性肿瘤(HR 2.13,95%CI 1.61-2.83,P < .001)的独立因素。
- 年龄增加和吸烟亦与事件估计升高相关(P < .001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Second malignancy is a rare but potentially lethal event after prostate brachytherapy, but data remain scarce on its long-term risk. The objective of this study is to estimate the number of pelvic second malignancies following brachytherapy compared to radical prostatectomy (RP). MATERIALS AND METHODS: We retrospectively reviewed patients treated with low-dose 125I brachytherapy and RP in British Columbia from 1999 to 2010. Kaplan-Meier estimates for pelvic (bladder and rectum), invasive pelvic, any second malignancy, and death from any second malignancy were assessed. Cox multivariable analyses were performed adjusting for initial treatment type, age, post-RP adjuvant/salvage external beam radiation therapy status, and smoking history. RESULTS: Two thousand three hundred seventy-eight brachytherapy and 9089 RP patients were included. Median age was 66 years (interquartile range [IQR] 61-71) and 63 years (IQR 58-67), respectively. Median follow-up time to event or censured was 14 years (IQR 11.5-17.3). The Kaplan-Meier estimates for pelvic second malignancy at 15 and 20 years were 6.4% and 9.8%, respectively, after brachytherapy, and 3.2% and 4.2% after RP. Time to any second malignancy and time to death from any second malignancy were not significantly different (P > .05). On Cox multivariable analysis, brachytherapy, compared to surgery, was an independent factor for pelvic (hazard ratio [HR] 1.81 [95% CI 1.45-2.26], P < .001) and invasive pelvic second malignancy (HR 2.13 [95% CI 1.61-2.83], P < .001). Increased age and smoking were also associated with higher estimates of events (P < .001). CONCLUSIONS: After adjustment for age, post-RP adjuvant/salvage external beam radiation therapy status, and smoking status, numerically higher long-term HRs of pelvic and invasive pelvic second malignancy in patients treated with brachytherapy compared to RP were noted.
引用
- St-Laurent MP, Acland G, Hamilton SN, et al. Long-Term Second Malignancies in Prostate Cancer Patients Treated With Low-Dose-Rate Brachytherapy and Radical Prostatectomy. J Urol. 2024. PMID: 38603578. doi:10.1097/JU.0000000000003965
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。